Novacyt S.A. Liquidity Agreement and Total Voting Rights (7409Q)
March 01 2021 - 9:30AM
UK Regulatory
TIDMNCYT
RNS Number : 7409Q
Novacyt S.A.
01 March 2021
Novacyt S.A.
("Novacyt" or the "Company")
Liquidity Agreement Monthly Update and Total Voting Rights
Paris, France and Camberley, UK - 1 March 2021 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces its monthly update in relation to
ordinary shares traded under its ongoing liquidity agreement with
Invest Securities SA (the "Liquidity Agreement"). The Liquidity
Agreement is governed by French law and is further summarised in
the 'notes for editors' section below.
During the period from 1 February to 28 February 2021, Invest
Securities purchased 6,395 ordinary shares at a maximum price of
EUR9.90 and a minimum price of EUR7.80 and sold 4,520 ordinary
shares at a maximum price of EUR10.12 and a minimum price of
EUR7.72 under the Liquidity Agreement. The total number of ordinary
shares in the Company, which are held in treasury as at close of
business on 28 February 2021, is 5,272.
Total Voting Rights
The total number of ordinary shares in the Company is
70,626,248. This figure may be used by shareholders as the
denominator for calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not
subject to the disclosure guidance and transparency rules made by
the Financial Conduct Authority under Part VI of FSMA.
For further information, please refer to www.novacyt.com or contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
Further information on the Liquidity Agreement
On 12 September 2016, the Company and Invest Securities entered
into the Liquidity Agreement pursuant to which Invest Securities
provides liquidity services in relation to the ordinary shares to
the Company. Invest Securities may purchase ordinary shares on
behalf of the Company under the agreement, subject to approval from
Shareholders as to the price at which ordinary shares can be
brought back and the aggregate amount that the Company may provide
to Invest Securities to purchase such ordinary shares.
Shareholder approval was granted at the Shareholders' meeting
held on 29 September 2020 for the purchase of ordinary shares by
Invest Securities under the agreement at a maximum purchase price
per ordinary shares of EUR12.00 for an aggregate maximum purchase
price of EUR200,000 and for 18 months from the date of the
approval. Under the agreement, Invest Securities must act
completely independently of the Company and the Company must not
communicate with the employees of Invest Securities who are
responsible for performing the agreement. Invest Securities is paid
EUR10,000 per annum for its services under the liquidity agreement.
The agreement has an initial term of two years, with a rolling
extension of one year thereafter. The agreement can be terminated
by either party at the end of each such period subject to two
months' prior notice. The Liquidity Agreement is governed by French
law. Ordinary shares purchased by Invest Securities are either
cancelled or held as treasury shares (which are non-voting and do
not rank for dividends).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRZFLFBFXLBBBD
(END) Dow Jones Newswires
March 01, 2021 09:30 ET (14:30 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Sep 2023 to Sep 2024